Atara en­lists Juno co-founder Michel Sade­lain in CAR-T ef­fort; Valeant no more, Bausch is the new mar­quee name

→ The day af­ter Atara an­nounced that it is bring­ing Genen­tech vet Di­et­mar Berg­er on board as R&D chief, the biotech is back with a signed deal aimed at ex­pand­ing its work with Memo­r­i­al Sloan Ket­ter­ing on off-the-shelf CAR-Ts. As part of that arrange­ment, Atara is get­ting an ex­clu­sive re­la­tion­ship with Michel Sade­lain, the top CAR-T in­ves­ti­ga­tor who helped cre­ate the sci­en­tif­ic foun­da­tion for Juno. Said Sade­lain: “We are ea­ger to work with Atara to con­tin­ue ad­vanc­ing promis­ing al­lo­gene­ic T-cell im­munother­a­py tech­nolo­gies that orig­i­nat­ed at MSK. The new CAR T tech­nolo­gies seek to over­come per­sis­tent ther­a­peu­tic chal­lenges, such as safe­ty and tol­er­a­bil­i­ty, dura­bil­i­ty of treat­ment re­sponse, and ac­tiv­i­ty in ar­eas of sig­nif­i­cant un­met med­ical need that are un­der­served by the cur­rent gen­er­a­tion of CAR T im­munother­a­pies.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.